Study Asks Whether Cook’s Esophageal Stent can be Removed

The prospect of removing an esophageal stent may be slightly daunting, but that’s what Cook Medical is investigating with a new US clinical study involving its supposedly retrievable new offering.


Cook’s study to evaluate the removability of its new Evolution® Esophageal Fully Covered Stent is the first multicenter U.S. study to evaluate the possibility of removing a self-expanding metal stent after malignant and benign strictures have been treated. The stent design used in the study has been modified to accommodate retrieval. The study will also evaluate the use of the device in esophageal conditions, including strictures, fistulas, perforations or leaks.

The study is being led by Principal Investigator and paid consultant to Cook Medical, Dr. John Vargo MD, MPH, chairman of Gastroenterology and Hepatology at the Cleveland Clinic. It is a prospective, single-arm study into which patients can be enrolled when they require a stent for an obstruction that is caused by an intrinsic or extrinsic malignancy or a refractory benign esophageal stricture. Also, patients that have an esophageal fistula, perforation or leak can be included in the study. There are additional eligibility criteria for the study.

The Evolution Esophageal study will be conducted at up to 15 sites across the U.S. and will enroll 130 patients. Patients will be followed for the duration of stent placement up to six months. After endoscopic stent removal, specified patients will have a 30-day follow-up that will complete his or her enrollment.

Physician comments

“Defining the role of removable stents in benign and malignant esophageal disorders is still a quandary for clinicians,” said Dr. Vargo. “This multicenter study which involves many of the leading centers in therapeutic endoscopy, should help answer this question.”

Company comments

“We are very excited to see where this study takes us,” said Barry Slowey, global leader of Cook Medical’s Endoscopy division. “We hope that the results of this study will allow for some expanded treatment options for malignant and benign esophageal diseases.”

Source: Cook Medical, Inc., Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *